STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD (GPCR) rallied 5.14% in the intraday session on Wednesday, driven by positive analyst coverage from H.C. Wainwright.
H.C. Wainwright initiated coverage on GPCR with a Buy rating and an $80 price target. According to analysts polled by FactSet, GPCR has an average Buy rating and a mean price target of $86.73, implying significant upside potential.
The bullish analyst calls highlight GPCR's focus on developing oral obesity medications, a promising therapeutic area with substantial market potential. Positive view on the company's pipeline and growth prospects appear to be fueling optimism among investors.